Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
The results after tax for the last year were, however, decidedly smaller for Probi than last year, just SEK 8 million, compared to SEK 24.5 million last year. Per share this lands at SEK 0,85, a mere fourth of last year’s profit of SEK 2,62 per share. The cash flow was quite stable for Probi, SEK 13.9 million for this fiscal year, compared to SEK 13 million for the last. Among the most important things this year was the positive results from the clinical study program for Lp299v as treatment for ordinary cold. Last year Probi was also rewarded a research grant of SEK 1.8 million from Vinnova, for a research program on the cardiovascular health effects of probiotics.